INTRODUCTION
============

*Acinetobacter* spp. are ubiquitous in the environment and have emerged as important opportunistic pathogens that cause nosocomial infections \[[@B1]\]. Currently, more than 30 named and unnamed species of *Acinetobacter* have been identified by DNA-DNA hybridization \[[@B2]\]. *Acinetobacter baumannii*, which is the most frequently identified species from clinical infections and outbreaks, is genetically closely related and phenotypically similar to 2 other clinical species, namely, *Acinetobacter* genomic species (gen. sp.) 3 and 13TU and to *Acinetobacter calcoaceticus*, a soil bacterium. This close similarity led to the proposal that these species should be grouped together in the so-called *A. calcoaceticus-A. baumannii* (Acb) complex \[[@B3]\]. With the exception of *A. calcoaceticus*, all members of this complex have been reported to be involved in nosocomial infections and are known to have the ability to spread within hospitals \[[@B4]\].

Acb complex has now become a major cause of hospital-acquired infections worldwide due to its remarkable propensity to rapidly acquire determinants of resistance to a wide range of antibacterial agents \[[@B5]\]. In particular, increasing resistance to carbapenems has been observed worldwide in the past decade. Carbapenemase production is the best-described mechanism of resistance to carbapenems, and various metallo-β-lactamases (MBLs) and OXA-type carbapenemases have been isolated from Acb complex strains worldwide \[[@B6]-[@B8]\]. In some instances, carbapenemase genes, such as *bla*~IMP~, *bla*~VIM~, *bla*~GIM~, or *bla*~SIM~, are located within class 1 integrons and lead to carbapenem resistance. Multidrug-resistant Acb complex strains have been known to acquire their antimicrobial resistance genes via class 1 integrons that carry single or multiple gene cassettes \[[@B9]\].

Aminoglycoside resistance genes, such as acetyltransferase (*aac*), phosphotransferase (*aph*), and adenylyltransferase (*aad*), are also typically found within integron gene cassettes \[[@B10]\]. In addition, Acb complex strains carry various types of aminoglycoside-modifying enzymes (AMEs) and 16S rRNA methylases, which confer resistance to aminoglycosides \[[@B11]\].

Increases in the number of fluoroquinolone-resistant Acb complex strains are mediated primarily by spontaneous mutations in the quinolone resistance-determining regions (QRDRs) of either DNA gyrase (*gyrA*), topoisomerase IV (*parC*), or both \[[@B12]\].

Although the Acb complex has been recognized as an important opportunistic pathogen associated with life-threatening nosocomial infections and hospital outbreaks, there is a relative paucity of data on the number and type of resistance genes in Acb complex strains isolated in Daejeon, Korea. In the present study, we aimed to determine the genetic basis for multidrug resistance and the clonal relatedness of the Acb complex clinical isolates obtained from a university hospital in Daejeon. Molecular determinants enabling the multidrug resistant strains to exhibit co-resistance to carbapenems, aminoglycosides, and fluoroquinolones were investigated with a focus on integrons, carbapenemases, AMEs, 16S rRNA methylase, and mutations of the *gyrA* and *parC* genes.

MATERIALS AND METHODS
=====================

1. Bacterial isolates and *rpoB* gene analysis
----------------------------------------------

A total of 56 consecutive and non-duplicate imipenem-nonsusceptible Acb complex isolates were collected from the university hospital laboratory in Daejeon, Korea, from January 2008 to December 2010. *Acinetobacter* spp. were identified by using the Vitek 2® automated ID system (BioMérieux, Marcy l\'Etoile, France) and partial sequencing of the *rpoB* housekeeping gene, as described previously \[[@B13]\].

2. Antimicrobial agents and minimum inhibitory concentration (MIC) determinations
---------------------------------------------------------------------------------

The MICs of Acb complex isolates for imipenem, meropenem, gentamicin, amikacin, ceftazidime, cefepime, and ciprofloxacin were determined using Etest (BioMérieux). Interpretation was based on the criteria approved by the CLSI \[[@B14]\]. *Escherichia coli* ATCC 25922 was used as the reference strain.

3. Characterization of antimicrobial resistance determinants
------------------------------------------------------------

All Acb complex isolates were subjected to PCR and sequencing assays for the detection of antimicrobial resistance determinants and the identification of mutations associated with fluoroquinolone resistance. Specific primers for the detection of antimicrobial resistance determinants were used \[[@B15]-[@B18]\]. Chromosomal DNA was obtained from each target strain by using a genomic DNA purification kit (Promega, Madison, WI, USA) in accordance with standard protocols. PCR was performed using 50 ng of genomic DNA, 2.5 µL of 10× Taq buffer, 0.5 µL of 10 mM dNTP mix, 20 pmol of each primer, and 0.7 U of Taq DNA polymerase (SolGent, Daejeon, Korea), in a total volume of 25 µL. Each antimicrobial resistance determinant gene was amplified in a GeneAmp PCR System 9600 thermal cycler (Perkin-Elmer Cetus Corp., Norwalk, CT, USA) by pre-denaturation of the reaction mixture at 95℃ for 5 min, followed by 35 cycles of 95℃ for 30 sec, 52℃ for 40 sec, and 72℃ for 30 sec, with a final extension at 72℃ for 5 min. The amplicons were purified with a PCR purification kit (SolGent) and were sequenced using a BigDye Terminator Cycle Sequencing Kit (PE Applied Biosystems, Foster City, CA, USA) and an ABI PRISM 3730XL DNA analyzer (PE Applied Biosystems). Integron detection, characterization, and gene cassette amplification were carried out using previously described PCR methods \[[@B19]\].

4. Repetitive extragenic palindromic PCR (REP-PCR) for clonality assessment
---------------------------------------------------------------------------

In the REP-PCR method, the primer pair of REP1 (5\'-IIIGCGCCGICATCAGGC-3\') and REP2 (5\'-ACGTCTTATCAGGCCTAC-3\') was used to amplify putative REP-like elements in the genomic DNA \[[@B20]\]. Amplification reactions were performed in a final volume of 50 µL, containing 100 ng of chromosomal DNA, 5 µL of 10× Taq buffer, 1.0 µL of 10 mM dNTP mix, 1.5 U of Taq DNA polymerase (SolGent), and 50 pmol of each primer. The cycling conditions were as follows: an initial denaturation step at 95℃ for 5 min; followed by 30 cycles of 92℃ for 50 sec, 48℃ for 55 sec, and 70℃ for 5 min; and a final extension step at 70℃ for 10 min. The amplified products were separated via electrophoresis on 1.5% agarose gels containing ethidium bromide, and visualized using a BioDoc-14™ Imaging system (UVP, Cambridge, UK).

RESULTS
=======

1. Identification of *Acinetobacter* spp
----------------------------------------

Isolates were assigned to 3 distinct *Acinetobacter* species on the basis of the results of *rpoB* gene analysis: *A. baumannii* (N=44), *Acinetobacter* gen. sp. 3 (N=10), and *Acinetobacter* gen. sp. 13TU (N=2). The distribution of MICs for imipenem, meropenem, amikacin, ceftazidime, and cefepime was similar among *A. baumannii*, *Acinetobacter* gen. sp. 3, and *Acinetobacter* gen. sp. 13TU. However, high-level resistance to gentamicin (MIC~50~≥1,024 mg/L) and ciprofloxacin (MIC~50~≥32 mg/L) was only seen in the *A. baumannii* isolates ([Table 1](#T1){ref-type="table"}).

2. Detection and characterization of integrons
----------------------------------------------

Most of the Acb complex isolates (94.6%) contained class 1 integrons, which ranged between 1.8 and 3.0 kb in length. However, no class 2 or class 3 integrons were found within the cohorts. The gene cassettes found in this study were divided into 4 types by nucleotide sequencing ([Fig. 1](#F1){ref-type="fig"}). The type 1 amplicon (3.0 kb), obtained in 10 *Acinetobacter* gen. sp. 3 isolates, carried *aacA4*-*bla*~IMP-1~-*bla*~OXA-2~ gene cassettes. The type 2 amplicon (3.0 kb), found in 2 *Acinetobacter* gen. sp. 13TU isolates, carried *bla*~VIM-2~-*aacA7*-*aadA1* gene cassettes. The type 3 amplicon (1.8 kb), detected in only 1 *Acinetobacter* gen. sp. 13TU isolate, carried *aac3-1-bla*~OXA-2~-orfD gene cassettes. Forty-one *A. baumannii* isolates (93.2%) contained the type 4 amplicon (2.3 kb) carrying *aacA4-catB8-aadA1* gene cassettes.

3. Carbapenem resistance genes in Acb complex isolates
------------------------------------------------------

The distribution of carbapenem resistance genes among isolates of the 3 different *Acinetobacter* species is shown in [Table 2](#T2){ref-type="table"}. The *bla*~OXA-23~ gene was only amplified from 21 *A. baumannii* isolates (47.7%), all of which harbored the upstream insertion element IS*Aba1* and were highly resistant to imipenem (MICs≥32). The intrinsic β-lactamase gene, *bla*~OXA-51~-like, was amplified in all 44 *A. baumannii* isolates, and an upstream IS*Aba1* was identified in 39 strains (88.6%). Other OXA-type carbapenemase genes, such as *bla*~OXA-24~ and *bla*~OXA-58~-like, were not found in this study.

Two MBL genes, *bla*~IMP-1~ and *bla*~VIM-2~, were detected in *Acinetobacter* gen. sp. 3 and 13TU. The *bla*~SIM~ gene was not detected in any of our isolates. All imipenem-nonsusceptible Acb complex isolates contained more than 1 carbapenemase gene.

4. Aminoglycoside resistance genes in Acb complex isolates
----------------------------------------------------------

Three different genes encoding AMEs were identified: *aac(6\')-Ib* was the most prevalent, found in 52 isolates, followed by *aph(3\')-Ia* in 31 isolates, and *aph(3\')-VI* in 12 isolates ([Table 3](#T3){ref-type="table"}). All 10 *Acinetobacter* gen. sp. 3 isolates contained *aac(6\')-Ib* and *aph(3\')-VI*, whereas 31 *A. baumannii* isolates had the combination of *aac(6\')-Ib/aph(3\')-Ia*. The 16S rRNA methylase gene *armA* was detected in 41 *A. baumannii* isolates, but *rmtA* and *rmtB* were not detected in any Acb complex isolates tested. The 41 *A. baumannii* isolates containing *armA* were highly resistant to amikacin (MIC~50~≥256 mg/L) and gentamicin (MIC~50~≥1,024 mg/L).

The 3 *A. baumannii* isolates that did not contain integrons or 16S rRNA methylase and AMEs had low-level aminoglycoside resistance, with an amikacin MIC~50~ of 4 mg/L and a gentamicin MIC~50~ of 8 mg/L.

5. Characterization of quinolone resistance among Acb complex isolates
----------------------------------------------------------------------

All *A. baumannii* isolates had sense mutations at the 83rd residue (serine to leucine) in *gyrA* and at the 80th residue (serine to leucine or tryptophan) in *parC*, and had high-level ciprofloxacin resistance (MIC~50~≥32 mg/L). However, sense mutations in *parC* were not detected in *Acinetobacter* gen. sp. 3 and 13TU isolates. The sense mutations at the 83rd residue (serine to leucine) in *gyrA* were detected in only 8 *Acinetobacter* gen. sp. 3 isolates, which had low-level ciprofloxacin resistance (MIC~50~=4 mg/L). The 3 *Acinetobacter* gen. sp. isolates without sense mutations in either *gyrA* or *parC* were susceptible to ciprofloxacin (MIC~50~=0.19 mg/L).

6. REP-PCR patterns
-------------------

To determine the clonality of all 56 Acb complex isolates, REP-PCR was performed on genomic DNA. The 44 *A. baumannii* isolates displayed only 2 REP-PCR types, designated type A and type B ([Fig. 2](#F2){ref-type="fig"}). However, the *Acinetobacter* gen. sp. 3 and 13TU isolates showed diverse band patterns.

DISCUSSION
==========

This study analyzed various genes of Acb complex isolates that are responsible for resistance to carbapenems, aminoglycosides, and fluoroquinolones. Previous studies focused mainly on carbapenem or aminoglycoside resistance \[[@B11]\]. We found differences in the genetic characteristics of isolates from 3 different *Acinetobacter* species in terms of their carbapenem, aminoglycoside, and fluoroquinolone resistance.

Our study identified several differences in carbapenem resistance genes among *Acinetobacter* spp. isolates. OXA-type carbapenemase genes (*bla*~OXA-23~ and *bla*~OXA-51~-like) were only observed in *A. baumannii* isolates, while MBL genes (*bla*~IMP-1~ or *bla*~VIM-2~) were only present in *Acinetobacter* gen. sp. 3 or 13TU isolates. This distribution is in accordance with previous reports of resistance genes among *Acinetobacter* spp. \[[@B21], [@B22]\]. The presence of IS*Aba1* upstream of *bla*~OXA~ genes provides a promoter sequence enhancing their expression \[[@B23]\]. In isolates possessing *bla*~OXA-23~, IS*Aba1* was consistently associated with *bla*~OXA-23~ and not with the *bla*~OXA-51~-like gene, suggesting that coexpression of these 2 genes does not occur. The dissemination of *A. baumannii* isolates harboring the *bla*~OXA-23~ gene has been previously reported in Korea \[[@B15], [@B24]\]. In addition, class 1 integrons harboring MBL genes were detected in *Acinetobacter* gen. sp. 3 and 13TU isolates. A 3.0-kb class 1 integron containing *bla*~IMP-1~ with *aacA4* and *bla*~OXA-2~ was described in *A. baumannii* (EF375699) and *A. junii* (EU014166) isolates recovered from Korea in 2007. In our previous study, we reported that multidrug resistant *A. baumannii* isolates contained class 1 integrons harboring *bla*~IMP-1~ with *aacA4* and *bla*~OXA-2~ \[[@B15]\]. However, an *A. baumannii* isolate harboring *bla*~IMP-1~ was not detected in the present study. A 3.0-kb class 1 integron containing *bla*~VIM-2~ with *aacA7* and *aadA1* was described in *A. baumannii* (AF324464) recovered from Korea in 2002 \[[@B25]\].

In our study, significant variation was seen in the distribution of aminoglycoside resistance genes among *Acinetobacter* gen. sp. isolates. The *armA* and *aph(3\')-Ia* genes were only detected in *A. baumannii* isolates, whereas *aph(3\')-VI* was only detected in *Acinetobacter* gen. sp. 3 and 13TU isolates. In particular, *A. baumannii* isolates containing *armA* showed high-level gentamicin resistance (MIC~50~≥1,024 mg/L). Unlike AMEs, which vary in their substrate ranges, 16S rRNA methylases confer high-level resistance to almost all clinically important aminoglycosides \[[@B11]\]. The *armA* gene was previously detected in *A. baumannii*, *P. aeruginosa*, *E. coli*, *K. pneumoniae*, and *S. marcescens* \[[@B26]\], but has not been detected in other *Acinetobacter* gen. sp. so far.

A major mechanism of fluoroquinolone resistance in gram-negative bacteria involves changes in the structure of the drug targets, DNA gyrase and DNA topoisomerase IV \[[@B27]\]. In particular, amino acid substitutions in both the *GyrA* and *ParC* polypeptides are consistent with a high-level fluoroquinolone resistant phenotype \[[@B28]\]. In this study, all 44 *A. baumannii* isolates harboring sense mutations in both *gyrA* and *parC* showed high-level resistance to ciprofloxacin (MIC~50~≥32 mg/L). These results are similar to those reported in our study of multidrug resistant *A. baumannii* isolates \[[@B15]\].

In addition, identical banding patterns on REP-PCR profiles were only seen among the *A. baumannii* isolates. Our results suggest that there is both clonal and horizontal spread of resistance genes between imipenem-nonsusceptible *A. baumannii* isolates in the university hospital in Daejeon.

Despite the increasingly frequent discovery of multidrug resistant *Acinetobacter* spp. isolates in Korea, there is a relative paucity of information regarding the antimicrobial resistance of this gram-negative bacillus in Daejeon. Although we found differences in genetic characteristics of isolates from 3 different *Acinetobacter* species, most (87.5%) of them possessed integrons, AMEs, carbapenemases, and mutations in *gyrA*. The co-occurrence of several resistance determinants may present a significant threat.
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###### 

The MIC distribution of 7 antimicrobial agents for the 56 *A. calcoaceticus-baumannii* complex isolates as determined by Etest
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Abbreviation: MIC, minimum inhibitory concentration.
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Distribution of carbapenemase genes in imipenem-nonsusceptible *Acinetobacter calcoaceticus-baumannii* complex isolates
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###### 

Distribution of aminoglycoside resistance genes in imipenem-nonsusceptible *Acinetobacter calcoaceticus-baumannii* complex isolates
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